Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Announces Highlights from Analyst Event

GlobeNewswire November 18, 2021

ProQR to Webcast Virtual Analyst Event on November 18

GlobeNewswire November 11, 2021

ProQR Announces Upcoming Investor Conferences in November and December

GlobeNewswire November 8, 2021

ProQR Announces Third Quarter 2021 Operating and Financial Results

GlobeNewswire November 4, 2021

ProQR Appoints Theresa Heggie as Chief Commercial Officer

GlobeNewswire October 4, 2021

ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

GlobeNewswire September 8, 2021

ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

GlobeNewswire September 8, 2021

ProQR Announces Virtual Presentation at EURETINA 2021

GlobeNewswire September 6, 2021

ProQR Announces Upcoming Investor Conferences

GlobeNewswire September 3, 2021

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

GlobeNewswire August 11, 2021

ProQR Announces Second Quarter 2021 Operating and Financial Results

GlobeNewswire August 5, 2021

ProQR to Present at Upcoming JMP Securities Life Sciences Conference

GlobeNewswire June 10, 2021

ProQR Announces First Quarter 2021 Operating and Financial Results

GlobeNewswire May 6, 2021

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

GlobeNewswire April 23, 2021

ProQR Announces Participation in Upcoming Kempen Life Sciences Conference

GlobeNewswire April 22, 2021

ProQR Announces Annual Meeting of Shareholders

GlobeNewswire April 20, 2021

ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

GlobeNewswire April 13, 2021

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire April 5, 2021

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

GlobeNewswire April 2, 2021

ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

GlobeNewswire March 30, 2021